Airway diseases
Interstitial lung diseases
Oral presentation
Innovative approaches to managing asthma and chronic obstructive pulmonary disease: a translational perspective
Translational
Methods :
Endoscopy and interventional pulmonology, Imaging, Pulmonary function testing, Pulmonary rehabilitation, Transplantation, General respiratory patient care, Physiology, Cell and molecular biology
11:00
Late Breaking Abstract - Early improvement in asthma small airway dysfunction after one dose of SAR443765, a novel bispecific anti-thymic stromal lymphopoietin/anti-IL-13 nanobody molecule
A. Deiteren(Gent, Belgium)
COI
1
11:05
Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy
W. Zuo(Shanghai, China)
COI
2
11:10
Relationship between IL-33 expression and epithelial remodelling in COPD small airways
S. Booth(WHITE - English/Welsh/Scottish/Northern Irish or B, United Kingdom)
COI
3
11:15
A novel senotherapeutic approach for COPD via activating autophagy-lysosome axis
S. Matsubayashi(Tokyo, Japan)
COI
4
11:20
SIL-6Rα amplified IL-6 signaling in bronchial epithelial cells defines a subgroup of asthma patients low in sputum eosinophils
R. Gosens(Groningen, Netherlands)
COI
5
11:25
Mepolizumab alters the phenotype and activation status of peripheral blood eosinophils in patients with severe eosinophilic asthma
P. Miguéns-Suárez(Santiago de Compostela, Spain)
COI
6
11:30
Effect of add-on therapies (mepolizumab, omalizumab or azithromycin) on asthma remission in severe asthma
D. Thomas(New Lambton Heights, Australia)
COI
7
11:35
Effect of in vitro azithromycin treatment on epithelial antiviral immunity in eosinophilic and non-eosinophilic asthma phenotypes
M. Ghanizada(Copenhagen, Denmark)
COI
8
11:40
NK cell maturation and proliferation in severe asthmatic patients after Benralizumab therapy
L. Bergantini(siena, Italy)
COI
9
11:45
The inhaled PDE4 inhibitor tanimilast shows efficacy in both Th2 and non-Th2 murine models of asthma
A. Pisano(Parma (PR), Italy)
COI
10
11:50
Discussion and Q&A
11
OA4306
. . .
